Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up

Neri, B; Cini, G; Andreoli, F; Boffi, Bernardo; Francesconi, Daniela; Mazzanti, Roberto; Medi, F.; A, Mercatelli; Romano, Salvatore Mario; Siliani, Luisa Margherita; Tarquini, Roberto; Moretti, Renato

doi:10.1054/bjoc.2000.1472

Cited by 71 publications

(39 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are a few reports on the effectiveness of adjuvant chemotherapy for gastric cancer. (7)(8)(9) It is important to identify patients with apparent early-stage disease who will not be cured by surgery alone and, con- In conclusion, most patients survive without recurrent disease after Resection A surgery for gastric cancer and chemotherapy did not increase survival rate after Resection A surgery. In selecting the patients for adjuvant therapy, both the stage of gastric cancer and the quality of surgery should be considered.…”

Section: Discussionmentioning

confidence: 99%

Resection A Surgery: An Exclusion Criterion of Adjuvant Treatment for Gastric Cancer

Chung

2010

J Korean Surg Soc

View full text Add to dashboard Cite

Purpose:We evaluated the clinical implication of Resection A surgery retrospectively to identify whether quality of surgery can be used as a selection factor for adjuvant therapy in patients with gastric cancer. Methods: Prognosis of 902 patients with gastric cancer who underwent Resection A surgery was evaluated. Results: Among all discharged patients, 77 patients (8.5%) died of recurrent disease, 55 patients (6.1%) died without recurrent disease. Five-year survival rate of all discharged patients was 91.6% and 10-year survival rate 87.1%. Statistically significant prognostic factors were depth of invasion (P＜0.001), lymph node metastasis (P＜ 0.001), stage (P＜0.001), tumor location (P=0.036) and size (P=0.001), extent of gastric resection (P＜0.001), and chemotherapy (P＜0.001) on univariate analyses. However, depth of invasion (P=0.001), lymph node metastasis (P＜0.001), and total gastrectomy (P＜0.001) emerged as statistically significant poor prognostic factor on a multivariate analysis. Adjuvant chemotherapy did not increase the survival rate of patients after Resection A surgery, even in patients with stage II disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Resection A Surgery: An Exclusion Criterion of Adjuvant Treatment for Gastric Cancer

Chung

2010

J Korean Surg Soc

View full text Add to dashboard Cite

show abstract

“…However, RCTs published after 2000 have consisted of primarily combinations of cisplatin and FU. Collectively, S1 or 5-FU-cisplatin combination regimens in neo-adjuvant, adjuvant, and perioperative settings have yielded a favourable impact on survival [20][21][22][23][24][25][26][27][28][29][30][31][32] . Moreover, chemotherapy seems to provide prolongation of survival for patients with mostly node-positive and T3-T4 disease ( Table 1).…”

Section: Adjuvant Chemotherapy Regimensmentioning

confidence: 99%

Current adjuvant treatment modalities for gastric cancer: From history to the future

Kılıç

Ordu

Yıldız

et al. 2016

WJGO

View full text Add to dashboard Cite

The discrepancy between the surgical technique and the type of adjuvant chemotherapy used in clinical trials and patient outcomes in terms of overall survival rates has led to the generation of different adjuvant treatment protocols in distinct parts of the world. The adjuvant treatment recommendation is generally chemoradiotherapy in the United States, perioperative chemotherapy in the United Kingdom and parts of Europe, and chemotherapy in Asia. These options mainly rely on the United States Intergroup-0116, United Kingdom British Medical Research Council Adjuvant Gastric Infusional Chemotherapy, and the Asian Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer and Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer trials. However, the benefits were evident for only certain patients, which were not very homogeneous regarding the type of surgery, chemotherapy regimens, and stage of disease. Whether the dissimilarities in survival are attributable to surgical technique or intrinsic biological differences is a subject of debate. Regardless of the extent of surgery, multimodal therapy may offer modest survival advantage at least for diseases with lymph node involvement. Moreover, in the era of individualized treatment for most of the other cancer types, identification of special subgroups comprising those who will derive more or no benefit from adjuvant therapy merits further investigation. The aim of this review is to reveal the historical evolution and future reflections of adjuvant treatment modalities for resected gastric cancer patients. Core tip: Despite extensive surgery, gastric cancer will likely recur for most patients. Fortunately, additional treatment modalities either in the perioperative or postoperative setting provide varying degrees of survival

show abstract

“…[24][25][26] The challenge today for investigators is how best to incorporate the lessons learned from the recent successes of various trials like Intergroup 0116 trial and the Medical Research Council's (MRC) Magic trial.…”

Section: Etiopathogenesismentioning

confidence: 99%

Pathogenesis and treatment of Gastric Carcinoma: “An up-date with brief review”

Aziz¹,

Nath²,

Sivaselvam³

2007

IJO

View full text Add to dashboard Cite

show abstract

Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up

Cited by 71 publications

References 7 publications

Resection A Surgery: An Exclusion Criterion of Adjuvant Treatment for Gastric Cancer

Resection A Surgery: An Exclusion Criterion of Adjuvant Treatment for Gastric Cancer

Current adjuvant treatment modalities for gastric cancer: From history to the future

Pathogenesis and treatment of Gastric Carcinoma: “An up-date with brief review”

Contact Info

Product

Resources

About